Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Interest & Investment Income (2023 - 2025)

Monte Rosa Therapeutics' Interest & Investment Income history spans 3 years, with the latest figure at $3.7 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 42.16% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $12.9 million, up 22.49%, while the annual FY2025 figure was $12.9 million, 22.49% up from the prior year.
  • Interest & Investment Income reached $3.7 million in Q4 2025 per GLUE's latest filing, up from $2.7 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $3.7 million in Q4 2025 to a low of $2.2 million in Q3 2023.
  • Average Interest & Investment Income over 3 years is $2.7 million, with a median of $2.6 million recorded in 2024.
  • The largest YoY upside for Interest & Investment Income was 42.16% in 2025 against a maximum downside of 5.05% in 2025.
  • A 3-year view of Interest & Investment Income shows it stood at $2.4 million in 2023, then increased by 9.59% to $2.6 million in 2024, then surged by 42.16% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Interest & Investment Income are $3.7 million (Q4 2025), $2.7 million (Q3 2025), and $3.1 million (Q2 2025).